FibroBiologics announces first board of directors



“As we continue to accelerate the development of our clinical programs in degenerative disc disease, orthopedics, multiple sclerosis and cancer, we are fortunate to attract highly respected industry leaders to our mission,” said Pete O’Heeron, President / Founder / CEO. “Our Board of Directors includes a wide range of talented executives with backgrounds across the biotech community. Their leadership will guide us through the development, regulatory and commercialization processes with the goal of bringing these life-changing therapies to patients with pain.

FibroBiologics board members include:

Rich cilento, MBA – Chairman and CEO of GlycosBio, Inc., entrepreneur

Stacy coen, MBA – SVP, Chief Business Officer of Immunogen, Inc., Director of the Board of Directors of Huntington American Society of Diseases (HDSA)

Robert hoffmann, CPA – Chairman of Kintara Therapeutics and member of the board of directors of ASLAN Pharmaceuticals and Antibe Therapeutics

Matthew Link, BSE – Managing Director Orion Healthcare Advisors, former President NuVasive

Victoria niklas, MD – Vice President, Global Program Leader R&D, Plasma Derived Therapies Unit, Takeda Pharmaceuticals

Pete O’Heeron, MSHA – President / Founder / CEO FibroBiologics, University of Chicago, University of houston-CL, Texas State University

For more detailed biographies on individual Council members, please visit our website:

About FibroBiologics

Situated at Houston, texas, FibroBiologics is a regenerative medicine company that develops an innovative solution for the treatment of chronic diseases using fibroblast cells. Currently, FibroBiologics holds over 150 patents / patents issued in the US and overseas in a variety of clinical pathways including disc degeneration, orthopedics, multiple sclerosis, and cancer. FibroBiologics represents the next generation of medical advancements in cell therapy.


SOURCE FibroBiologics

Related links



Comments are closed.